Kirsten T Eriksen1, Jane A McElroy2, James M Harrington3, Keith E Levine3, Camilla Pedersen1, Mette Sørensen1, Anne Tjønneland1, Jaymie R Meliker4, Ole Raaschou-Nielsen1,5. 1. Danish Cancer Society Research Center, Copenhagen, Denmark. 2. Family and Community Medicine Department, University of Missouri, Columbia, MO, USA. 3. Analytical Sciences Division, Research Triangle Institute, Research Triangle Park, NC, USA. 4. Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony Brook University, NY, USA. 5. Department of Environmental Science, Aarhus University, Roskilde, Denmark.
Abstract
Background: Cadmium is a human lung carcinogen, and recent evidence suggests it may play a role in hormone-related cancers because of its estrogenic activity. Case-control studies consistently show higher cadmium concentrations in urine from women diagnosed with breast cancer compared with control women. Our aim was to investigate the association between urinary cadmium and breast cancer in a prospective design. Methods: We conducted a case-cohort study using the population-based Danish Diet Cancer and Health Cohort. Women age 50 to 64 years were recruited in 1993-1997 and provided urine for analysis. We identified 900 incident case patients in the Danish Cancer Registry and compared with 898 individuals in a subcohort. Urine samples collected at enrollment into the cohort were analyzed for cadmium and creatinine. We estimated incidence rate ratios (IRRs) for breast cancer in Cox proportional hazards models with age as time axis and calculated 95% confidence intervals (CIs). Results: The linear analysis showed no association between urinary cadmium and risk for breast cancer (IRR = 1.00, 95% CI = 0.81 to 1.24 per ng Cd/mL urine). The categorical analyses showed a slightly higher risk for breast cancer for the second (IRR = 1.10, 95% CI = 0.86 to 1.42) and third (IRR = 1.14, 95% CI = 0.83 to 1.55) exposure tertiles compared with the lowest tertile. Results were similar in analyses of breast cancer subtypes defined by estrogen and progesterone receptor status and by histology, and analyses stratified by years from baseline to diagnosis. Conclusions: This large prospective study showed no association between urinary concentration of cadmium and subsequent risk for development of postmenopausal breast cancer.
Background: Cadmium is a human lung carcinogen, and recent evidence suggests it may play a role in hormone-related cancers because of its estrogenic activity. Case-control studies consistently show higher cadmium concentrations in urine from women diagnosed with breast cancer compared with control women. Our aim was to investigate the association between urinary cadmium and breast cancer in a prospective design. Methods: We conducted a case-cohort study using the population-based Danish Diet Cancer and Health Cohort. Women age 50 to 64 years were recruited in 1993-1997 and provided urine for analysis. We identified 900 incident case patients in the Danish Cancer Registry and compared with 898 individuals in a subcohort. Urine samples collected at enrollment into the cohort were analyzed for cadmium and creatinine. We estimated incidence rate ratios (IRRs) for breast cancer in Cox proportional hazards models with age as time axis and calculated 95% confidence intervals (CIs). Results: The linear analysis showed no association between urinary cadmium and risk for breast cancer (IRR = 1.00, 95% CI = 0.81 to 1.24 per ng Cd/mL urine). The categorical analyses showed a slightly higher risk for breast cancer for the second (IRR = 1.10, 95% CI = 0.86 to 1.42) and third (IRR = 1.14, 95% CI = 0.83 to 1.55) exposure tertiles compared with the lowest tertile. Results were similar in analyses of breast cancer subtypes defined by estrogen and progesterone receptor status and by histology, and analyses stratified by years from baseline to diagnosis. Conclusions: This large prospective study showed no association between urinary concentration of cadmium and subsequent risk for development of postmenopausal breast cancer.
Authors: Katie M O'Brien; Alexandra J White; Brian P Jackson; Margaret R Karagas; Dale P Sandler; Clarice R Weinberg Journal: Am J Epidemiol Date: 2019-04-01 Impact factor: 4.897
Authors: Katie M O'Brien; Alexandra J White; Brian P Jackson; Margaret R Karagas; Dale P Sandler; Clarice R Weinberg Journal: Am J Epidemiol Date: 2019-11-01 Impact factor: 4.897
Authors: Katie M O'Brien; Alexandra J White; Dale P Sandler; Brian P Jackson; Margaret R Karagas; Clarice R Weinberg Journal: Epidemiology Date: 2019-01 Impact factor: 4.822
Authors: Sabrina A Rocco; Lada Koneva; Lauren Y M Middleton; Tasha Thong; Sumeet Solanki; Sarah Karram; Kowit Nambunmee; Craig Harris; Laura S Rozek; Maureen A Sartor; Yatrik M Shah; Justin A Colacino Journal: Toxicol Sci Date: 2018-08-01 Impact factor: 4.849
Authors: Nina Roswall; Ulla A Hvidtfeldt; James Harrington; Keith E Levine; Mette Sørensen; Anne Tjønneland; Jaymie R Meliker; Ole Raaschou-Nielsen Journal: Int J Environ Res Public Health Date: 2018-06-26 Impact factor: 3.390
Authors: Nicole M Niehoff; Katie M O'Brien; Alexander P Keil; Keith E Levine; Chamindu Liyanapatirana; Laura G Haines; Suramya Waidyanatha; Clarice R Weinberg; Alexandra J White Journal: Am J Epidemiol Date: 2021-11-02 Impact factor: 4.897